281 related articles for article (PubMed ID: 35012430)
1. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.
Mouritzen MT; Junker KF; Carus A; Ladekarl M; Meldgaard P; Nielsen AWM; Livbjerg A; Larsen JW; Skuladottir H; Kristiansen C; Wedervang K; Schytte T; Hansen KH; Østby AC; Frank MS; Lauritsen J; Sørensen JB; Langer SW; Persson GF; Andersen JL; Homann PH; Kristensen EB; Drivsholm LB; Bøgsted M; Christensen HS; Pøhl M; Bjørnhart B
Acta Oncol; 2022 Apr; 61(4):409-416. PubMed ID: 35012430
[TBL] [Abstract][Full Text] [Related]
2. 5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy.
Bjørnhart B; Mouritzen MT; Kristiansen C; Schytte T; Wedervang K; Pøhl M; Holmskov Hansen K
Acta Oncol; 2023 Aug; 62(8):861-870. PubMed ID: 37534770
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
4. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
Molinier O; Besse B; Barlesi F; Audigier-Valette C; Friard S; Monnet I; Jeannin G; Mazières J; Cadranel J; Hureaux J; Hilgers W; Quoix E; Coudert B; Moro-Sibilot D; Fauchon E; Westeel V; Brun P; Langlais A; Morin F; Souquet PJ; Girard N
ESMO Open; 2022 Feb; 7(1):100353. PubMed ID: 34953398
[TBL] [Abstract][Full Text] [Related]
5. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy.
Mouritzen MT; Carus A; Ladekarl M; Meldgaard P; Nielsen AWM; Livbjerg A; Larsen JW; Skuladottir H; Kristiansen C; Wedervang K; Schytte T; Hansen KH; Østby AC; Frank MS; Lauritsen J; Sørensen JB; Langer SW; Persson GF; Andersen JL; Frary JMC; Drivsholm LB; Vesteghem C; Christensen HS; Bjørnhart B; Pøhl M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638329
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Real-World Data from an Academic Central and Eastern European Center.
Ivanović M; Knez L; Herzog A; Kovačević M; Cufer T
Oncologist; 2021 Dec; 26(12):e2143-e2150. PubMed ID: 34288239
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
[No Abstract] [Full Text] [Related]
8. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
Juarez-Garcia A; Sharma R; Hunger M; Kayaniyil S; Penrod JR; Chouaïd C
Lung Cancer; 2022 Apr; 166():205-220. PubMed ID: 35316754
[TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Rousseau A; Tagliamento M; Auclin E; Aldea M; Frelaut M; Levy A; Benitez JC; Naltet C; Lavaud P; Botticella A; Grecea M; Chaput N; Barlesi F; Planchard D; Besse B
Eur J Cancer; 2023 Mar; 182():107-114. PubMed ID: 36758475
[TBL] [Abstract][Full Text] [Related]
13. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
Murakami Y; Tamiya A; Taniguchi Y; Adachi Y; Enomoto T; Azuma K; Inagaki Y; Kouno S; Matsuda Y; Okishio K; Atagi S
Thorac Cancer; 2022 Feb; 13(4):593-601. PubMed ID: 34989133
[TBL] [Abstract][Full Text] [Related]
16. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
18. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
[TBL] [Abstract][Full Text] [Related]
19. Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.
Veraldi M; Esposito S; Naturale MD; Oradei M; Cosco D; Francesco AE; Cicchetti A; Bidino RD
J Oncol Pharm Pract; 2021 Jun; 27(4):877-886. PubMed ID: 32686615
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
